An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

Nainani, Viveka; Galal, Ushma; Buttery, Jim; Snape, Matthew D.

doi:10.1136/archdischild-2017-312941

Cited by 31 publications

(38 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current published data suggest that the 4CMenB vaccine has limited, if any, effect on the carriage of MenB [112]. Although the 4CMenB vaccine is reactogenic [113], recent surveillance data do not support initial concerns with respect to increased risk of Kawasaki disease and seizures [114]. The 4CMenB vaccine has the potential to offer protection against meningococci belonging to other serogroups.…”

Section: Importance Of Menb Protein Vaccinesmentioning

confidence: 99%

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Acevedo

Bai

Borrow

et al. 2018

Expert Review of Vaccines

159

View full text Add to dashboard Cite

2019) The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and highrisk populations, Expert Review of Vaccines, 18:1, 15-30, ABSTRACT Introduction: The 2018 Global Meningococcal Initiative (GMI) meeting focused on evolving invasive meningococcal disease (IMD) epidemiology, surveillance, and protection strategies worldwide, with emphasis on emerging antibiotic resistance and protection of high-risk populations. The GMI is comprised of a multidisciplinary group of scientists and clinicians representing institutions from several continents. Areas covered: Given that the incidence and prevalence of IMD continually varies both geographically and temporally, and surveillance systems differ worldwide, the true burden of IMD remains unknown. Genomic alterations may increase the epidemic potential of meningococcal strains. Vaccination and (to a lesser extent) antimicrobial prophylaxis are the mainstays of IMD prevention. Experiences from across the globe advocate the use of conjugate vaccines, with promising evidence growing for protein vaccines. Multivalent vaccines can broaden protection against IMD. Application of protection strategies to high-risk groups, including individuals with asplenia, complement deficiencies and human immunodeficiency virus, laboratory workers, persons receiving eculizumab, and men who have sex with men, as well as attendees at mass gatherings, may prevent outbreaks. There was, however, evidence that reduced susceptibility to antibiotics was increasing worldwide. Expert commentary: The current GMI global recommendations were reinforced, with several other global initiatives underway to support IMD protection and prevention. ARTICLE HISTORY

show abstract

Section: Importance Of Menb Protein Vaccinesmentioning

confidence: 99%

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Acevedo

Bai

Borrow

et al. 2018

Expert Review of Vaccines

159

View full text Add to dashboard Cite

show abstract

“…Active AEFI surveillance studies often use linked data; exposure information (vaccination) from vaccination registry are linked with prespecified outcomes of interest identified from electronic records using computerised International Classification of Diseases (ICD) diagnosis codes . Moreover, studies also suggest that vaccine safety signals can be tracked using proxy measures of AEFI occurrences, such as postvaccination health care utilisation/medical attendance rate …”

Section: Introductionmentioning

confidence: 99%

“…6 Moreover, studies also suggest that vaccine safety signals can be tracked using proxy measures of AEFI occurrences, such as postvaccination health care utilisation/medical attendance rate. 7,8 The ICD-10-CM (10th revision, clinical modification) contains diagnostic codes assigned for AEFI-related diagnoses, such as T80.5…”

Section: Introductionmentioning

confidence: 99%

Positive predictive value of ICD‐10 codes to detect anaphylaxis due to vaccination: A validation study

Mesfin

Cheng

Tran

et al. 2019

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

Purpose To validate the use of selected International Classification of Disease Codes 10th revision (ICD‐10) to predict (positive predictive value) anaphylaxis due to vaccination using emergency department (ED) data. Methods We conducted a retrospective study using ED encounter data from a large tertiary‐care teaching hospital, Monash Medical Centre, Melbourne, Australia. We searched all ED encounters potentially due to anaphylaxis after vaccination, between 1 January 2010 and 31 December 2018, using ICD‐10‐CM codes T80.5, T80.6, T88.1, T88.6, and T78.2. Health records of potential cases were examined to determine if they met the Brighton Collaboration (BC) criteria for anaphylaxis. We calculated the PPV to evaluate the accuracy of the selected ICD‐10‐CM codes in predicting anaphylaxis due to vaccination. Results Of the 69 health records identified and reviewed, 29 (42.2%) met the criteria for anaphylaxis regardless of the cause, and 24.6% (17/69) of records were confirmed as anaphylaxis triggered by vaccination (low positive predictive value). However, of the 23 records identified using ICD‐10‐CM code T80.5, 22 were classified as anaphylaxis cases regardless of the cause, and 12 were anaphylaxis due to vaccination cases giving PPV of 95.7% and 52.2%, respectively. Conclusions Given that there is no specific ICD‐10‐CM code for anaphylaxis due to vaccination, ICD‐10‐CM code T80.5 may be suitable to monitor anaphylaxis due to vaccination in the ED setting. The current study was conducted at a single centre and needs to be confirmed by future multicentre studies.

show abstract

“…In retrospective1 and prospective2 audits, Nainani et al (n=38) and Kapur et al (n=35) demonstrated significant increases in emergency department (ED) attendances (0.8% of the local vaccinated population2), investigations (venepuncture in 38%1 and 62%,2 lumbar puncture (LP) in 22%1 and 17%2) and hospitalisations (72%1 and 51%2 (for post-immunisation fever). Murdoch et al ’s3 self-controlled case series estimated an additional 1440 hospital admissions per year in the UK following 4CMenB introduction.…”

mentioning

confidence: 99%

4CMenB and post-immunisation fever: an emerging hot topic

et al. 2018

View full text Add to dashboard Cite

An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study

Abstract: The increase in emergency department attendances, investigations and antibiotic use for AEFIs following 4CMenB immunisation may influence the cost-effectiveness of the 4CMenB immunisation campaign.

Cited by 31 publications

References 5 publications

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations

Positive predictive value of ICD‐10 codes to detect anaphylaxis due to vaccination: A validation study

4CMenB and post-immunisation fever: an emerging hot topic

Contact Info

Product

Resources

About